MATT MOWERS: Following the NATO Summit, Europe’s Easy Benefit Is at Risk

Europe’s Dependence on American Generosity

For many years, countries in Europe have leaned heavily on America’s strength, innovation, and generosity, often without contributing their fair share in return. They accept our protection, products, technology, and financial support, while still critiquing us on issues like democracy and the economy.

This situation feels unbalanced, to say the least. The Americans seem to bear the burden.

Europe imposes high tariffs and numerous regulations on American goods, from agriculture to cars, effectively swamping the market with subsidized products. The EU doesn’t seem to target American high-tech companies for misconduct but rather, simply because they are successful. This isn’t about healthy competition; rather, it’s like an economic roadblock.

But that’s not all. European nations benefit from American investments and standards while paying much less for the same prescription drugs produced by U.S. companies. Foreign government officials arbitrarily decide drug prices, determining which ones to cover, leaving many American patients to bear the financial weight. A staggering percentage of new medications are accessible to only 43% of patients in other wealthy nations, compared to 87% in the U.S. This set of policies damages American patients by forcing them to shoulder the costs that others avoid.

Recent analysis shows that 26% of U.S. drug prices go toward compensating for costs that other countries evade, essentially a hidden tax that U.S. patients have endured over the years.

The elites in Washington and Brussels seem eager to keep things as they are, yet Americans are becoming aware of the unfairness. They are ready for a leader who will prioritize American interests. It’s time to demand respect for our contributions rather than apologize for our might.

President Trump’s approach indicates that the era of free reign for Europe is nearing its end. His unconventional vision for NATO and international trade continues to resonate, supported by figures like Vice President J.D. Vance. Their push for fair contributions and accountability exemplifies the need for a new wave of conservative leadership willing to challenge globalist attitudes.

Enough is enough. The current administration seems overly focused on gaining European approval while expanding government control, essentially allowing other regions to exploit American resources. A significant factor in President Trump’s success in key swing states was the resentment toward this imbalance.

Trump was often unafraid to express what others avoided. America seems to be misled, and now is the time to push back.

With Trump and Vance confronting unfair trade practices, the current focus must be on healthcare. This entails tackling foreign influence and reshoring supply chains, starting by pressuring Europe and other affluent nations to contribute fairly. By leveraging U.S. government resources, we can encourage these countries to invest more in innovative medical solutions. Fair trade agreements should equate to just pricing, thereby ending the free ride for certain countries.